Last Wednesday, Biogen executives told Fierce Biotech the company was becoming “the new Biogen” through external partnerships and acquisitions. Five days later, the company wrote a billion dollar check for RayThera to prove it meant what it said. That is not a coincidence. Biogen clearly had this deal in the works when it gave that interview, and the messaging was designed to prepare the market for exactly this kind of move. RayThera brings immunology assets into a company that has been defined by neuroscience for its entire existence. Spinraza. Tecfidera. Leqembi. All neurology. All developed largely in house. Now Biogen is buying its way into a completely different therapeutic area, and it is doing it at speed. Combine this with the felzartamab consolidation ($850 million, TJ Biopharma), the salanersen Breakthrough Therapy designation for SMA, and the diranersen Phase 3 advancement in Alzheimer’s, and Biogen has deployed more than $2 billion in pipeline building this year. The FDA formally accepted UniQure’s Huntington’s disease gene therapy for accelerated approval review. Moderna’s mRNA flu vaccine cleared the advisory committee. And BIO International opens today in San Diego.
Biogen Buys RayThera for Up to $1B and Enters Immunology
Five days. That is how long it took Biogen to go from talking about “the new Biogen” to actually being it.
The company announced on June 21 that it is acquiring RayThera for up to $1 billion, bringing immunology pipeline assets into a company that has spent its entire history building neuroscience drugs. The deal is the fastest follow through on a stated strategy pivot from any large biotech this year.
The strategic logic is straightforward. The autoimmune and inflammatory disease market is one of the largest in pharma. AbbVie’s Dupixent. Pfizer’s JAK inhibitors. The entire Rinvoq and Skyrizi franchise that is carrying AbbVie through the post Humira transition. These are massive commercial opportunities. Biogen has the scale, the commercial infrastructure, and the payer relationships to compete in this space. What it has lacked is the pipeline. RayThera addresses that gap.
But the question is whether a company built on neuroscience can successfully operate in immunology. The physicians are different. Neuroscience means neurologists and psychiatrists. Immunology means rheumatologists, dermatologists, and gastroenterologists. The payer dynamics are different. The competitive landscape is different. And the internal culture—the way scientists think about disease, the way medical affairs teams interact with physicians, the way commercial teams build relationships—all of that has to adapt. Companies that have successfully diversified across therapeutic areas (Lilly moving from metabolic disease into oncology, for example) prove it can be done. But it requires genuine organizational commitment, not just a press release.
What makes this deal credible is the pattern. Biogen is not making a single move and calling it a strategy. It is building a portfolio through multiple transactions. Felzartamab ($850 million) for kidney disease. RayThera (up to $1 billion) for immunology. Salanersen (Breakthrough Therapy) for SMA. Diranersen (Phase 3 advancement) for Alzheimer’s. Each move is different in size and therapeutic area, but they share a common thread: Biogen is looking outside its own walls for the next generation of its pipeline. The “new Biogen” is real. Whether it works is the next question.
Our Pro brief assesses what RayThera brings to Biogen’s portfolio, analyzes whether a neuroscience company can successfully diversify into immunology, and evaluates the competitive positioning against established players. [Details below.]
FDA Accepts UniQure’s Huntington’s Gene Therapy Filing
Two weeks ago, the FDA told UniQure it needed data from an additional trial before it would accept a filing for AMT 130 in Huntington’s disease. Last week, the agency reversed that position and agreed to accept the existing dataset. This week, the filing is formally in and under review for accelerated approval.
That is a remarkable regulatory trajectory for a program targeting one of the most devastating diseases in medicine.
Huntington’s disease affects approximately 30,000 Americans. It is caused by a single genetic mutation—an expanded CAG repeat in the huntingtin gene—that produces a toxic protein destroying neurons in the brain. The disease typically appears in a patient’s 30s or 40s and progresses relentlessly through motor dysfunction, cognitive decline, and psychiatric symptoms over 15 to 20 years. There are no approved disease modifying treatments. Every prior therapeutic approach—antisense oligonucleotides, small molecule huntingtin lowering agents, gene silencing—has failed or remains in early development.
AMT 130 takes a fundamentally different approach. It uses an AAV5 viral vector injected directly into the brain to deliver a microRNA that reduces production of the mutant huntingtin protein believed to cause the disease. Rather than managing symptoms or trying to slow decline, the therapy addresses the genetic root cause.
The accelerated approval pathway is significant because it allows the FDA to evaluate AMT 130 based on a surrogate endpoint—likely reduction in mutant huntingtin protein levels—rather than requiring years of data demonstrating clinical benefit in a slowly progressive disease. A regulatory decision could come by late 2026 or early 2027.
If approved, AMT 130 would be one of the most important gene therapy approvals in history. Not because of the market size (Huntington’s is a small patient population) but because of what it would represent: the first disease modifying treatment for a fatal neurodegenerative condition with a clearly identified genetic cause. The precedent would extend far beyond Huntington’s to every genetically defined neurological disease where gene therapy could intervene at the root cause rather than treating the consequences.
Moderna’s mRNA Flu Vaccine Clears the Advisory Committee
The final regulatory hurdle before an approval decision is now behind Moderna. An FDA advisory committee voted positively on the company’s experimental mRNA flu vaccine on Thursday, and Moderna shares closed up 3.5% on the news.
This follows the positive FDA briefing documents we covered on Friday, which indicated the shot met key study goals in adults 65 and older—the population that accounts for the majority of flu hospitalizations and deaths. The advisory committee’s endorsement is typically the last step before the FDA makes a formal approval decision, which could come within weeks to months.
If approved, this would be the first mRNA seasonal flu vaccine on the U.S. market. The significance goes well beyond one product. An approved mRNA flu vaccine validates the platform for routine commercial use—not emergency pandemic response, but annual seasonal production at scale. The manufacturing advantages are meaningful: mRNA vaccines can be designed and produced faster than traditional egg based alternatives, potentially allowing better alignment between the vaccine strain and the circulating flu strains each season. The current flu vaccine manufacturing process takes six or more months, leading to frequent strain mismatches that reduce effectiveness.
For Moderna, which built its market capitalization on COVID vaccines but needs to demonstrate platform breadth for long term commercial sustainability, a seasonal flu vaccine is the single most important product approval the company can achieve. It transforms Moderna from a pandemic response company into a platform vaccine company with recurring annual revenue.
Neumora Drops Its Lead Depression Drug After Phase 3 Failure
Not everything is working. Neumora Therapeutics dropped development of navacaprant after the drug missed both primary and key secondary endpoints in a Phase 3 study for major depressive disorder. The company had already cut 35% of its workforce the previous week. BioSpace reported the Phase 3 miss sent shares “spiraling” in premarket trading.
The failure leaves Neumora without its most advanced clinical asset and raises serious questions about the company’s path forward. A biotech that has already reduced headcount by more than a third and then loses its lead program is in a fundamentally precarious position. The options narrow quickly: find another program to advance (expensive and time consuming), pursue a merger or acquisition (potentially at a distressed valuation), or wind down operations.
The Neumora story is a useful counterweight to the optimism elsewhere in the industry. PwC declared biopharma “back to full health.” IPOs are raising $400 million plus. M&A exceeds $115 billion. But clinical failure remains the single largest risk in drug development, and no amount of favorable capital market conditions protects against a Phase 3 miss in a disease as biologically complex as depression. The history of depression drug development is littered with programs that showed promise in Phase 2 and failed in Phase 3. Navacaprant joins that list.
Twelve IPOs, $4.1 Billion, and the Healthiest Market Since 2021
BioPharma Dive reported that twelve biotechs have gone public in 2026, raising a combined $4.1 billion—the largest total since 2021. This year’s IPO class has produced five of the six largest new biotech stock offerings since the start of 2022.
The numbers tell a story about the quality of the companies entering public markets, not just the quantity. Kailera raised $625 million with a Lilly partnership already in place. Parabilis raised $475 million with a Regeneron collaboration signed. Kardigan raised more than $400 million for a cardiovascular pipeline. These are not speculative early stage biotechs hoping for a pop on day one. They are well capitalized companies with validated science, existing pharma partnerships, and clinical data that gives public market investors something concrete to evaluate.
The IPO market’s health matters for the entire biotech ecosystem because it completes the capital cycle. Venture investors fund early innovation. IPOs provide public market liquidity. M&A delivers acquisition returns. When all three pathways are functioning—and in 2026, they are—the system produces a steady supply of clinical stage assets that large pharma companies need to fill their pipeline gaps. The $115 billion plus in M&A this year depends on a pipeline of acquisition targets, and that pipeline depends on a venture and IPO market that rewards innovation with capital.
BIO International Opens Today
The BIO International Convention opens today at the San Diego Convention Center and runs through June 25. More than 20,000 attendees are expected at the industry’s largest annual partnering event.
The conference comes at a moment of extraordinary industry momentum. M&A exceeds $115 billion. IPOs have raised $4.1 billion. PwC declared the ecosystem “back to full health.” Lilly has executed 13 deals. The China licensing pipeline exceeds $50 billion. ADCs, molecular glues, mRNA vaccines, and in vivo CAR T are all producing clinical data simultaneously. The conversations that happen in San Diego this week will shape the deals that close in the second half of the year.
We will cover significant announcements from BIO International in daily emails through the conference.
Strategic Themes
1. Biogen Proved That Strategy Announcements Mean More When They Come With a Check
Five days from “we are pivoting” to “$1 billion acquisition.” That sequencing was intentional and it was effective. The market now takes “the new Biogen” seriously because the company backed the words with capital. The lesson applies broadly: in an industry where every company claims to be transforming, the ones that write checks within days of making the claim earn credibility that press releases alone cannot buy.
2. UniQure’s FDA Reversal Is the Most Important Gene Therapy Regulatory Development of the Year
The FDA said no. Then it said yes. Then it formally accepted the filing. The reversal matters not just for Huntington’s patients (though it matters enormously for them) but for every gene therapy developer targeting a rare neurodegenerative disease. The precedent—that the FDA will accept a filing for accelerated approval based on existing data rather than demanding years of additional trials—could shorten development timelines for programs in ALS, Parkinson’s, and other genetically defined neurological conditions.
3. Moderna Clearing the Advisory Committee Puts the mRNA Platform on the Threshold of Routine Commercial Use
COVID proved mRNA works in an emergency. A seasonal flu vaccine approval would prove it works as a routine commercial product. That distinction matters for Moderna’s valuation, for the competitive dynamics of the flu vaccine market, and for the broader vaccine industry. If mRNA can make a better flu shot, it can make better vaccines for RSV, combination respiratory products, and future pandemic preparedness—all of which Moderna has in development.
4. Neumora Reminds Everyone That Phase 3 Failure Is Still the Biggest Risk in Biotech
The capital markets are healthy. The IPO window is open. M&A premiums are strong. But none of that matters if the drug does not work. Neumora lost its lead asset and a third of its workforce in the same month. The clinical risk in drug development is irreducible, and it is the reason that biotech investing—despite the favorable 2026 environment—remains fundamentally different from investing in established industries with predictable revenue streams.
Frequently Asked Questions
What is the Biogen/RayThera deal?
Biogen is acquiring RayThera for up to $1 billion to expand into immunology. This is the most significant action under the “new Biogen” strategy announced five days earlier. Combined with felzartamab ($850M), salanersen Breakthrough, and diranersen Phase 3, Biogen has deployed more than $2 billion in pipeline building this year.
What happened with UniQure?
The FDA formally accepted UniQure’s filing for AMT 130, a Huntington’s disease gene therapy, for accelerated approval review. This follows a reversal where the FDA dropped its demand for additional trial data. A decision could come by late 2026 or early 2027. Huntington’s has no disease modifying treatments.
Did Moderna’s flu vaccine get approved?
Not yet, but it cleared the most important remaining hurdle. An FDA advisory committee voted positively on the mRNA flu vaccine. The committee endorsement typically precedes a formal FDA approval decision within weeks to months. If approved, it would be the first mRNA seasonal flu vaccine in the U.S.
What happened to Neumora?
Navacaprant missed both primary and key secondary endpoints in a Phase 3 depression trial. The company had already cut 35% of its workforce. The failure leaves Neumora without its lead clinical asset.
How is the IPO market doing?
Twelve biotechs have raised $4.1 billion in 2026, the largest total since 2021. Five of the six largest new biotech offerings since 2022 came from this year’s class. The window is the healthiest in five years.
When is BIO International?
Today through June 25 in San Diego. More than 20,000 attendees expected. The industry’s largest annual partnering event.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
Biogen’s Immunology Expansion. We assess what RayThera brings and whether a neuroscience company can successfully build a commercial immunology franchise, compare the pivot to similar therapeutic area diversifications at other mid cap pharma companies, and evaluate whether the $2 billion plus in 2026 deployment is producing a coherent pipeline or a scattered collection of assets.
Huntington’s Gene Therapy. We analyze what accelerated approval means for AMT 130, how the AAV5 microRNA approach differs from prior failed Huntington’s therapies, and what the regulatory precedent means for the broader neurodegenerative gene therapy pipeline.
mRNA Beyond COVID. We assess the flu vaccine approval timeline, model the competitive impact on the established seasonal flu vaccine market, and evaluate what approval means for Moderna’s combination respiratory vaccine strategy and long term commercial thesis.
Plus: Neumora failure analysis, IPO market scorecard, BIO International preview and coverage plan, Revolution filing watch, and the updated catalyst calendar through H2 2026.
About BioMed Nexus
BioMed Nexus delivers institutional grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep dive analyses cut through the noise to deliver the strategic insights that drive better decision making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
